December 23, 2024 06:37 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Cylinder blast at a temple in Karnataka's Hubbali injures nine people | Kuwait PM personally sees off Modi at airport as Indian premier concludes two-day trip | Three pro-Khalistani terrorists, who attacked a police outpost in Gurdaspur, killed in an encounter | Who is Sriram Krishnan, an Indian-American picked by Donald Trump as US AI policy advisor? | Mohali building collapse: Death toll rises to 2, many feared trapped for 17 hours | 4-year-old killed after speeding car driven by a teen hits him in Mumbai | PM Modi attends opening ceremony of Arabian Gulf Cup in Kuwait | Jaipur gas tanker crash: Toll touches 14, 30 critical | Arrest warrant against former cricketer Robin Uthappa over 'PF fraud' | PM Modi emplanes for a visit to Kuwait

Glenmark Life Sciences Limited initial public offer to open on July 27

Jul 21, 2021, at 11:04 pm

Kolkata: Glenmark Life Sciences Limited, a manufacturer of active pharmaceutical ingredients, plans to open its Initial Public Offering (“Offer”) on July 27, 2021.

Glenmark Pharma receives ANDA approval for Fingolimod Capsules, 0.5 mg

Jun 19, 2020, at 04:44 pm

Mumbai/UNI:  Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India

May 12, 2020, at 07:55 pm

MUMBAI/PRNewswire -- Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India's drug regulator DCGI in late April. Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India. Favipiravir is a generic version of Avigan® of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government and private hospitals in India are being enrolled for the study. Glenmark estimates study completion by July/August 2020.